Slow-acting, disease-modifying osteoarthritis agents

Vet Clin North Am Small Anim Pract. 1997 Jul;27(4):863-81. doi: 10.1016/s0195-5616(97)50084-2.

Abstract

There is evidence to suggest that tetracyclines have benefit beyond their antimicrobial activity. The ability to inhibit metalloproteinase activity may provide a disease-modifying effect in OA, and available data suggest that further investigation is warranted. Controlled, double-blind, prospective clinical studies have not been completed. The canine cruciate ligament transection model studies are frequently cited as the most convincing in vivo evidence of a benefit of oral tetracycline therapy for the treatment of OA. Until more evidence becomes available, the use of tetracyclines as therapeutic agents for OA should be considered investigational.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / pharmacokinetics
  • Antirheumatic Agents / therapeutic use*
  • Autacoids / adverse effects
  • Autacoids / pharmacokinetics
  • Autacoids / therapeutic use*
  • Dog Diseases / drug therapy*
  • Dogs
  • Dose-Response Relationship, Drug
  • Glycosaminoglycans / adverse effects
  • Glycosaminoglycans / pharmacokinetics
  • Glycosaminoglycans / therapeutic use
  • Hyaluronic Acid / adverse effects
  • Hyaluronic Acid / pharmacokinetics
  • Hyaluronic Acid / therapeutic use
  • Osteoarthritis / drug therapy
  • Osteoarthritis / veterinary*
  • Pentosan Sulfuric Polyester / adverse effects
  • Pentosan Sulfuric Polyester / pharmacokinetics
  • Pentosan Sulfuric Polyester / therapeutic use
  • Tetracyclines / adverse effects
  • Tetracyclines / pharmacokinetics
  • Tetracyclines / therapeutic use

Substances

  • Antirheumatic Agents
  • Autacoids
  • Glycosaminoglycans
  • Tetracyclines
  • A73025
  • Pentosan Sulfuric Polyester
  • Hyaluronic Acid